Lung Cancer Archives | VJOncology

The Lung Cancer Channel on VJOncology is supported by Takeda and AstraZeneca. These supporters have no influence over the production of the content.

View overview page

The centralization of molecular testing

John Gosney • 8 Jul 2022

Updates in lung cancer management from the BTOG 2022 Summer Meeting

Riyaz Shah • 8 Jul 2022

Which subtypes of patients with mesothelioma are most likely to benefit from immunotherapy?

Riyaz Shah • 8 Jul 2022

Improving immunotherapy outcomes in mesothelioma

Riyaz Shah • 8 Jul 2022

The role of immunotherapy for the treatment mesothelioma

Riyaz Shah • 8 Jul 2022

Managing epithelial mesothelioma

Riyaz Shah • 8 Jul 2022

A real-world analysis on pembro monotherapy versus pembro + chemotherapy for never-smoking NSCLC

Sanjay Popat • 8 Jul 2022

The use of synthetic control arms to evaluate patients with rare oncogene-driven subsets in NSCLC

Sanjay Popat • 8 Jul 2022

Could ctDNA replace routine tissue testing for genotyping NSCLC?

Sanjay Popat • 8 Jul 2022

ctDNA-NGS versus routine tissue testing in patients with advanced NSCLC

Sanjay Popat • 8 Jul 2022

The British Thoracic Oncology Group (BTOG)

Sanjay Popat • 8 Jul 2022

The BTOG 2022 Summer Meeting

Sanjay Popat • 8 Jul 2022

Lessons learnt from a UK lung SABR rollout program

John Conibear • 8 Jul 2022

Challenges faced in the management of brain metastases and large cell neuroendocrine lung cancers

John Conibear • 8 Jul 2022

Lessons learnt from a UK lung SABR rollout program

John Gosney • 8 Jul 2022

The importance of biological understanding for disease management

John Gosney • 8 Jul 2022

1
2
Next